Germline News and Research

RSS

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

genOway and Griffith University sign research partnership and license for olfactory stem cells technology

genOway, the biotechnology company dedicated to the development of genetically modified animal models, today reports an agreement with the Griffith University (Brisbane, Australia) on a eight-months research partnership with its Eskitis Institute for Cell and Molecular Therapies focusing on autologous olfactory adult stem cells. This research program is coupled with a world wide exclusive license to genOway for the rodent transgenic business.

17 May 2010

StemCells first-quarter total revenue up 307%

StemCells, Inc., a leading stem cell technology company with the dual focus of novel therapeutics and innovative research products, today reported financial results for the first quarter ended March 31, 2010 and recent business highlights.

5 May 2010

Jumping elements in primates may have important consequences for studies of human genetic diseases

The density of transposable (jumping) elements between sex chromosomes in primates may have important consequences for the studies of human genetic diseases, say Penn State University researchers.

30 Apr 2010

Serametrix announces commercial launch of serum test for measuring serum antibodies

Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments.

16 Apr 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

BeaconEquity.com announces an investment report featuring biotech company StemCells Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

16 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

RainDance Technologies enters into strategic agreement with Applied Biosystems

RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for human health and disease research, and Applied Biosystems, part of Life Technologies Corporation, announced today they have entered into a strategic agreement to co-market the first solution that combines microdroplet PCR-based sequence enrichment with next-generation sequencing.

19 Feb 2010

Pure populations of immature cells that enable male reproduction isolated and transplanted

Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.

15 Dec 2009

Study on fruit flies may help in understanding the root cause of stem cell diseases

The body is a battle zone. Cells constantly compete with one another for space and dominance. Though the manner in which some cells win this competition is well known to be the survival of the fittest, how stem cells duke it out for space and survival is not as clear.

5 Dec 2009

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Credit Agricole Private Equity and VIB (the prestigious Flemish research institute).

3 Dec 2009

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

An analysis of patients with a syndrome similar to the genetic disorder, neurofibromatosis type 1, indicates that diagnosis may be difficult because of shared clinical findings, such as certain pigmentary characteristics, according to a study in the November 18 issue of JAMA.

19 Nov 2009

Scientists use new techniques to explore vocal learning at molecular level

You can learn a lot from an animal. By manipulating the DNA of mice, flies, frogs and worms, scientists have discovered a great deal about the genes and molecules behind many of life's essential processes. These basic functions often work about the same in people as they do in "model" animals.

30 Sep 2009

arGEN-X BV announces first closing of its Series A equity financing round

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody platform, today announced the successful first closing of its Series A equity financing round. The Company raised EUR 9.5million (~ USD 13.6 million) from a syndicate of leading life science investors. The financing round is one of the largest of its kind in the last 12 months.

10 Sep 2009

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Scientific dogma has long asserted that females are born with their entire lifetime's supply of eggs, and once they're gone, they're gone. New findings by researchers at Fred Hutchinson Cancer Research Center, published online Aug. 27 in Science, suggest that in nematode worms, at least, this does not hold true.

28 Aug 2009

Germline News and Research

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

genOway and Griffith University sign research partnership and license for olfactory stem cells technology

StemCells first-quarter total revenue up 307%

Jumping elements in primates may have important consequences for studies of human genetic diseases

Serametrix announces commercial launch of serum test for measuring serum antibodies

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

RainDance Technologies enters into strategic agreement with Applied Biosystems

Pure populations of immature cells that enable male reproduction isolated and transplanted

Study on fruit flies may help in understanding the root cause of stem cell diseases

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

Scientists use new techniques to explore vocal learning at molecular level

arGEN-X BV announces first closing of its Series A equity financing round

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Embryonic stem cells used to create human sperm

Chinese scientists use mouse stem cells to grow new eggs

microRNAs manipulate cells to one day create safe embryonic-like stem cells

Stem cells from human testes can change into other body tissues

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News